Type2 Diabetes
Conditions
Keywords
gut dysbiosis, rifaximin, insulin resistance
Brief summary
Gut Dysbiosis had been involved in some way in the pathogenesis of some extra-intestinal disorders including metabolic syndrome, cardiovascular disease, and obesity.
Detailed description
Accumulating evidence had linked metabolic syndrome and diabetes to dysequilibrium in gut microbiota, which are a critical regulator of host metabolism and immune responses. gut microbiota interacts with host signaling pathways, leading to modulation of the endocrine system, immune responses. gut microbial metabolites, in particular, short-chain fatty acids, have been significantly associated with liability to diabetes. patients with positive fecal short-chain fatty acids will be given rifaximin
Interventions
DRUGRifaximin 200 MG
patients with type 2 diabetes and gut dysbiosis will be given rifaximin
Sponsors
Zagazig University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* diabetes with gut dysbiosis
Exclusion criteria
* recent antibiotic use * pregnancy * diabetogenic drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| change in glycemic control | 3 months | Fasting blood sugar, post-prandial blood sugar (mg/dl) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Gastrointestinal symptom questionnaire | 1 month | symptomatic improvement in Dyspepsia, distension, abdominal pain |
Other
| Measure | Time frame | Description |
|---|---|---|
| change in weight | 6 months | Weight loss in kilograms |
Countries
Egypt
Contacts
Primary ContactAmr hanafy, MD
Outcome results
None listed